title: Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
abstract: OBJECTIVE
  To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).
  
  
  METHODS
  Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.
  
  
  RESULTS
  Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7% (95% confidence interval=7.7-25.7%). After a median follow-up of 73.5 months, 23 patients (34.8%) had experienced relapse. Five-year actuarial RFS and OS rates were 64% and 73%, respectively. Five-year actuarial RFS was 91.7% in the ypCR group versus 57.8% in non-ypCR cases.
  
  
  CONCLUSIONS
  Long-term local control and survival after this very well-tolerated regimen appear encouraging.
authors: S.C. di Oncologia Medica, Azienda Ospedaliero-Universitaria di Parma, via Gramsci 14, 43126 Parma, Italy. elisa_fontana@libero.it
authors: Elisa
authors: E
authors: Fontana
authors: Francesca
authors: F
authors: Pucci
authors: Roberta
authors: R
authors: Camisa
authors: Simona
authors: S
authors: Bui
authors: Salvatore
authors: S
authors: Galdy
authors: Francesco
authors: F
authors: Leonardi
authors: Francesca Virginia
authors: FV
authors: Negri
authors: Elisa
authors: E
authors: Anselmi
authors: Pier Luigi
authors: PL
authors: Losardo
authors: Luigi
authors: L
authors: Roncoroni
authors: Paolo
authors: P
authors: Dell'abate
authors: Pellegrino
authors: P
authors: Crafa
authors: Stefano
authors: S
authors: Cascinu
authors: Andrea
authors: A
authors: Ardizzoni
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000401:mortality / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil